Eagle Pharmaceuticals and USAMRICD Signs an Agreement for Ryanodex (dantrolene sodium)
Shots:
- United States Army Medical Research Institute of Chemical Defense (USAMRICD) and Eagle collaborates for evaluating the neuroprotective effects of Ryanodex
- Eagle will bear the research study cost and will be conducted under a Cooperative Research and Development Agreement (CRADA)- allowing government laboratories to partner with private industries or academia for R&D projects
- If approved post research study- Ryanodex will be a novel neuroprotective treatment for amelioration of neurological damage due to nerve agent exposure
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
